• NIFTY 11,588.35  (-0.63% )  
  • SENSEX 38,963.84  (-0.85%)  
  • USDINR 70.99  (-0.31%)  
  • GOLD 37,904.00  (0.04%)
  •  
  • Go
Corporate Information
Sun Pharma announces presentation of clinical data on ILUMYA (tildrakizumab-asmn)
(01 Mar 2019) Back
Sun Pharmaceutical Industries announced that one of its wholly owned subsidiaries presented new ILUMYA (tildrakizumab-asmn) clinical insights at the 2019 American Academy of Dermatology (AAD) Annual Meeting, including long-term data showing sustained skin clearance in some patients living with moderate-to-severe plaque psoriasis after three years of ongoing treatment with ILUMYA.